Tech Company Financing Transactions
Beacon Biosignals Funding Round
On 11/9/2021, Beacon Biosignals secured $27 million in Series A funding from General Catalyst Partners, Casdin Capital and private investors.
Transaction Overview
Company Name
Announced On
11/9/2021
Transaction Type
Venture Equity
Amount
$27,000,000
Round
Series A
Investors
General Catalyst Partners (Lead Investor) (Hemant Taneja)
private investors (Andrew Beck)
Proceeds Purpose
Proceeds will be used to scale Beacon's computational biomarker discovery platform and address the massive unmet need for quantitative clinical trial endpoints, safety tools, and computational diagnostics for neurology, psychiatry, and sleep medicine.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
80 Revere St. 10
Boston, MA 02114
USA
Boston, MA 02114
USA
Phone
Undisclosed
Website
Email Address
Overview
Beacon's machine learning platform for EEG enables and accelerates new treatments that transform the lives of patients with neurological, psychiatric or sleep disorders. Through novel machine learning algorithms, large datasets, and advances in software engineering, Beacon Biosignals is changing the way patients are treated for disorders of the brain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jacob Donoghue
Chief Technical Officer
Jarrett Revels
Co-Founder
Sydney Cash
Co-Founder
Brandon Westover
Browse more venture capital transactions:
Prev: 11/9/2021: HAPPE Spine venture capital transaction
Next: 11/9/2021: DeepCure venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. VC investment data records reported here come from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs